Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure

Background: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) reduce mortality and morbidity in patients with heart failure (HF), but are discontinued in some patients. Such patients may not enjoy favorable benefits of SGLT2i therapy. We evaluated the risk factors for SGLT2i discontinuation in a re...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakagaito, Masaki, Imamura, Teruhiko, Ushijima, Ryuichi, Nakamura, Makiko, Kinugawa, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046005/
https://www.ncbi.nlm.nih.gov/pubmed/36979855
http://dx.doi.org/10.3390/biomedicines11030876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046005/
https://www.ncbi.nlm.nih.gov/pubmed/36979855
http://dx.doi.org/10.3390/biomedicines11030876

Ejemplares similares